PsAID12 provisionally endorsed at OMERACT 2018 as core outcome measure to assess psoriatic arthritis-specific health-related quality of life in clinical trials
Objective. The Group for Research and Assessment of Psoriasis and Psoriatic Arthritis
(GRAPPA) and Outcome Measures in Rheumatology (OMERACT) psoriatic arthritis (PsA) …
(GRAPPA) and Outcome Measures in Rheumatology (OMERACT) psoriatic arthritis (PsA) …
A systematic review of measurement properties of patient reported outcome measures in psoriatic arthritis: a GRAPPA-OMERACT initiative
P Højgaard, L Klokker, AM Orbai, K Holmsted… - Seminars in arthritis and …, 2018 - Elsevier
Background An updated psoriatic arthritis (PsA) core outcome set (COS) for randomized
controlled trials (RCTs) was endorsed at the Outcome Measures in Rheumatology …
controlled trials (RCTs) was endorsed at the Outcome Measures in Rheumatology …
Updating the psoriatic arthritis (PsA) core domain set: a report from the PsA workshop at OMERACT 2016
Objective. To include the patient perspective in accordance with the Outcome Measures in
Rheumatology (OMERACT) Filter 2.0 in the updated Psoriatic Arthritis (PsA) Core Domain …
Rheumatology (OMERACT) Filter 2.0 in the updated Psoriatic Arthritis (PsA) Core Domain …
Use of telemedicine during the COVID-19 pandemic in patients with inflammatory arthritis: a retrospective study on feasibility and impact on patient-reported outcomes …
M Chevallard, L Belloli, N Ughi, A Adinolfi… - Rheumatology …, 2021 - Springer
Close follow-up is mandatory in patients with rheumatoid arthritis (RA), psoriatic arthritis
(PsA), and ankylosing spondylitis (AS). During the Coronavirus Disease 2019 (COVID-19) …
(PsA), and ankylosing spondylitis (AS). During the Coronavirus Disease 2019 (COVID-19) …
Effect of tofacitinib on patient-reported outcomes in patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors in the phase …
V Strand, K de Vlam, JA Covarrubias-Cobos… - RMD open, 2019 - rmdopen.bmj.com
Objectives Tofacitinib is an oral Janus kinase inhibitor for treatment of psoriatic arthritis
(PsA). Patient-reported outcomes (PROs) were evaluated in patients with PsA with …
(PsA). Patient-reported outcomes (PROs) were evaluated in patients with PsA with …
Higher coronary plaque burden in psoriatic arthritis is independent of metabolic syndrome and associated with underlying disease severity
A Szentpetery, GM Healy, D Brady… - Arthritis & …, 2018 - Wiley Online Library
Objective To examine the effect of metabolic syndrome and psoriatic disease–related
variables on coronary plaque burden in psoriatic arthritis (PsA) patients. Methods Fifty PsA …
variables on coronary plaque burden in psoriatic arthritis (PsA) patients. Methods Fifty PsA …
Tumor necrosis factor inhibitors in psoriatic arthritis
ABSTRACT Introduction: Psoriatic arthritis (PsA) is a chronic inflammatory disease that can
result in significant disability. With the emergence of tumor necrosis factor inhibitors (TNFi) …
result in significant disability. With the emergence of tumor necrosis factor inhibitors (TNFi) …
Secukinumab for psoriatic arthritis: comparative effectiveness versus licensed biologics/apremilast: a network meta-analysis
IB McInnes, P Nash, C Ritchlin… - Journal of …, 2018 - becarispublishing.com
Aim: A network meta-analysis using randomized controlled trial data compared psoriatic
arthritis (PsA) outcomes (American College of Rheumatology [ACR], Psoriasis Area Severity …
arthritis (PsA) outcomes (American College of Rheumatology [ACR], Psoriasis Area Severity …
Disease characteristics and the burden of joint and skin involvement amongst people with psoriatic arthritis: a population survey
Abstract Introduction Psoriatic arthritis (PsA) is a chronic, systemic, inflammatory disease
where disease burden and quality of life (QoL) are affected by both joint and skin …
where disease burden and quality of life (QoL) are affected by both joint and skin …
Real-world efficacy and safety of apremilast in Belgian patients with psoriatic arthritis: results from the prospective observational APOLO study
Introduction Apremilast is approved for the treatment of psoriasis and psoriatic arthritis (PsA).
Real-world evidence on the efficacy and safety of apremilast in clinical practice is limited …
Real-world evidence on the efficacy and safety of apremilast in clinical practice is limited …